European Journal of Cancer
Volume 46, Issue 1 , Pages 191-197 , January 2010

Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients

  • Mary G. Rhoads

      Affiliations

    • Department of Health Sciences, Boston University, Boston, MA, USA
    • ,
  • Susan C. Kandarian

      Affiliations

    • Department of Health Sciences, Boston University, Boston, MA, USA
    • ,
  • Fabio Pacelli

      Affiliations

    • Department of Surgery, Catholic University, Rome, Italy
    • ,
  • Giovan Battista Doglietto

      Affiliations

    • Department of Surgery, Catholic University, Rome, Italy
    • ,
  • Maurizio Bossola

      Affiliations

    • Department of Surgery, Catholic University, Rome, Italy
    • Corresponding Author InformationCorresponding author: Address: Istituto Clinica Chirurgica, Department of Surgery, Catholic University, Largo A.Gemelli, 8, 00168 Rome, Italy. Tel.: +390 630155485; fax: +390630155491.

Received 12 May 2009 ,Revised 26 September 2009

References 

  1. Bossola M, Pacelli F, Doglietto GB. Novel treatments for cancer cachexia. Expert Opin Invest Drugs. 2007;16(8):1241–1253
  2. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89(2):381–410
  3. Smith KL, Tisdale MJ. Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. Br J Cancer. 1993;67(4):680–685
  4. Costelli P, Reffo P, Penna F, et al. Ca(2+)-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol. 2005;37(10):2134–2146
  5. Argiles JM, Lopez-Soriano FJ, Busquets S. Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr Opin Support Palliat Care. 2007;1(4):293–298
  6. Belizario JE, Lorite MJ, Tisdale MJ. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer. 2001;84(8):1135–1140
  7. Bossola M, Pacelli F, Costelli P, et al. Proteasome activities in the rectus abdominis muscle of young and older individuals. Biogerontology. 2008;9(4):261–268
  8. Khal J, Hine AV, Fearon KC, Dejong CH, Tisdale MJ. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol. 2005;37(10):2196–2206
  9. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg. 2003;237(3):384–389
  10. Costelli P, Muscaritoli M, Bonetto A, et al. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest. 2008;38(7):531–538
  11. Moore-Carrasco R, Garcia-Martinez C, Busquets S, et al. The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia. FEBS Lett. 2006;580(2):691–696
  12. Matthys P, Heremans H, Opdenakker G, Billiau A. Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer. 1991;27(2):182–187
  13. Liu CM, Yang Z, Liu CW, et al. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 2007;14(12):945–952
  14. Cai D, Frantz JD, Tawa NE, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119(2):285–298
  15. Acharyya S, Butchbach ME, Sahenk Z, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 2005;8(5):421–432
  16. Kawamura I, Morishita R, Tomita N, et al. Intratumoral injection of oligonucleotides to the NF-kappaB binding site inhibits cachexia in a mouse tumor model. Gene Ther. 1999;6(1):91–97
  17. Wyke SM, Tisdale MJ. NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer. 2005;92(4):711–721
  18. Li YP, Schwartz RJ, Waddell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. Faseb J. 1998;12(10):871–880
  19. Li YP, Reid MB. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes [in process citation]. Am J Physiol Regul Integr Comp Physiol. 2000;279(4):R1165–R1170
  20. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia [see comments]. Science. 2000;289(5488):2363–2366
  21. Judge AR, Koncarevic A, Hunter RB, et al. Role for I{kappa}B{alpha}, but not c-Rel, in skeletal muscle atrophy. Am J Physiol Cell Physiol. 2007;292(1):C372–C382
  22. Hunter RB, Stevenson E, Koncarevic A, et al. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. Faseb J. 2002;16(6):529–538
  23. Hunter RB, Kandarian SC. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J Clin Invest. 2004;114(10):1504–1511
  24. Acharyya S, Ladner KJ, Nelsen LL, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest. 2004;114(3):370–378
  25. Siu PM, Alway SE. Mitochondria-associated apoptotic signalling in denervated rat skeletal muscle. J Physiol. 2005;565(565):309–323
  26. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25(51):6680–6684
  27. Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 1993;7(7B):1354–1363
  28. Bours V, Franzoso G, Azarenko V, et al. The oncoprotein Bcl-3 directly transactivates through kappaB motifs via association with DNA-binding p50B homodimers. Cell. 1993;72(5):729–739
  29. Baek SH, Ohgi KA, Rose DW, et al. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell. 2002;110(1):55–67
  30. Agusti A, Morla M, Sauleda J, Saus C, Busquets X. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax. 2004;59(6):483–487
  31. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci. 2005;30(1):43–52
  32. Ladner KJ, Caligiuri MA, Guttridge DC. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem. 2003;278(4):2294–2303[epub 002 November 12]
  33. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol. 2001;280(5):R1518–R1523
  34. Bossola M, Muscaritoli M, Bellantone R, et al. Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Invest. 2000;30(12):1107–1112
  35. Li YP, Lecker SH, Chen Y, et al. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. Faseb J. 2003;17(9):1048–1057
  36. Li YP, Chen Y, John J, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. Faseb J. 2005;19(3):362–370
  37. Wittekind CSL. TNM classification of malignant tumours. 6th ed.. New York: Wiley-Liss; 2002;

PII: S0959-8049(09)00733-3

doi: 10.1016/j.ejca.2009.10.008

European Journal of Cancer
Volume 46, Issue 1 , Pages 191-197 , January 2010

Article Tools

* Image Usage & Resolution